Official ESCRS | European Society of Cataract & Refractive Surgeons
London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Primitive eyelid merkel carcinoma: case report

Poster Details

First Author: A.Laborante ITALY

Co Author(s):    M. Gaspari   C. Longo   E. Mazzilli        

Abstract Details



Purpose:

We report the case of a 65-year-old Caucasian woman who came to us with a fast-growing neoplasm of the upper eyelid (of around 2.5 months).

Setting:

Ophthalmology Department IRCSS- Ospedale Casa Sollievo della Sofferenza S.Giovanni Rotondo-FG ITALY

Methods:

Primitive Merkel Cell Carcinoma (MCC) of the eyelid is a malign cutaneous neuro-endocrine tumour that originates in Merkel cells; these cells are situated along the border of the eyelid between the eyelashes. It is a rare, very aggressive and metastasising tumour. The histo-pathological diagnosis may require an immuno-histochemical and ultrastructural analysis. The authors describe the clinical case of a 65-year-old patient with palpebral MCC that appeared suddenly over a period of three months.

Results:

The correct therapeutic strategy for Merkel cell cancer is a radical, aggressive and early removal of the tumour at its initial stage, in order to reduce the risk of a distant recurrence and to improve the survival rate. The tumour must be resected with a broad safety margin and radiotherapy may be required post surgery.

Conclusions:

It is a very aggressive tumour that has a local recurrence in 25% of cases and metastasis to local lymph nodes in 30%. Distant metastasis may occur within two years of diagnosis (skin, bones, brain, liver and lungs). FINANCIAL INTEREST: NONE

Back to Poster listing